Have any clinical trials for Dr. Gupta’s Alzheimer’s formula been registered on ClinicalTrials.gov or WHO ICTRP?

1. What the major registries and recent pipeline reviews say

Comprehensive, peer-reviewed pipeline reviews — the 2025 Alzheimer’s disease drug development pipeline — rely on ClinicalTrials.gov as the primary source and report 182 trials and 138 candidate drugs on the index date (Jan 1, 2025), noting that AD trials “must be registered on clinicaltrials.gov” ^[1]. That review is the explicit, up-to-date inventory that researchers and journalists use to check whether a named therapy has a formal, registered trial ^{[2] [3]}.

2. Direct answer about “Dr. Gupta’s Alzheimer’s formula”

Available sources and the pipeline review do not mention any trial labeled “Dr. Gupta’s Alzheimer’s formula” on ClinicalTrials.gov or the WHO ICTRP; the reviewed registry-based survey and related reporting make no reference to such a registered trial ^{[1] [2]}. Because the pipeline review claims to catalog agents recorded on ClinicalTrials.gov, its silence on this formula is strong evidence that no registered, recognized AD trial by that name appeared in that index ^[1].

3. How to interpret absence of a registry entry

When a therapy is being developed legitimately for Alzheimer’s disease and is intended for human testing, standard practice — and legal/ethical expectations in many jurisdictions — is to register the trial on ClinicalTrials.gov or WHO ICTRP; the 2025 pipeline review treats registry listings as the authoritative record ^{[2] [1]}. Absence from these registries can mean at least three different things: no trial has been initiated; any testing is preclinical (lab or animal) and not a human trial; or a trial exists but has not been registered — the latter would be out of step with usual norms and with the reporting methods used in the reviewed literature ^{[2] [1]}.

4. What the registries would show if a trial existed

The pipeline review makes clear that ClinicalTrials.gov entries include phase, design, endpoints, and sponsor details and are the source for counting Phase 1–3 AD trials ^{[2] [1]}. Established sponsors (academic centers, biotech, pharma) routinely list NCT identifiers and trial details; coverage in reviews and conference materials typically cites those NCT numbers ^{[4] [5]}. If Dr. Gupta’s formula had a registered AD trial, it would normally appear with the same searchable fields and be picked up in the pipeline audits and conference reporting.

5. Alternative explanations and caveats

Available sources do not discuss any alternative record-keeping that would legitimately hide a registered human AD trial from ClinicalTrials.gov or WHO ICTRP; the reviewed literature assumes these registries are comprehensive for trials intended to support drug development and publication ^{[2] [1]}. It remains possible that an investigator-run, small, early-stage human study exists but was not included in the Jan 1, 2025 index date or was not registered — however, such an omission would be atypical and would also not show up in the sources you provided ^[1].

6. How you (or I) can confirm independently

To be definitive, search ClinicalTrials.gov and the WHO ICTRP directly for the investigator’s name, the formula’s chemical or common name, and sponsoring institution; review any listed NCT or ISRCTN identifiers and cross-check those with recent pipeline reviews and CTAD/ conference programs ^{[1] [6]}. The pipeline review and reporting from major meetings (CTAD) and trial sponsors normally cite trial IDs when trials are registered and underway ^{[1] [6]}.

7. Bottom line and journalistic read

The authoritative, registry-based 2025 pipeline review — which explicitly uses ClinicalTrials.gov to compile active AD trials — lists 182 trials and 138 candidate drugs but contains no mention of “Dr. Gupta’s Alzheimer’s formula” ^[1]. Therefore, based on the supplied sources, there is no evidence in the public registries or the referenced literature that a registered clinical trial for that formula exists; available sources do not mention such a trial ^{[2] [1]}. If you want a conclusive determination, the next journalistic step is a direct search of ClinicalTrials.gov and WHO ICTRP and, where possible, an inquiry to Dr. Gupta or their institution for documentation such as an NCT number.